3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
10
Lymphoid
9
Myeloid
3
Sarcoma
1
Other hematologic neoplasm
1
Classical hematology
1
Conditions
Anemia
116
Neoplasms
77
Anemia, Refractory, with Excess of Blasts
32
Myelodysplastic Syndromes
31
Leukemia, Myeloid, Acute
28
Venous Thromboembolism
25
Thrombocytopenia
24
Leukemia
22
Breast Neoplasms
22
Febrile Neutropenia
21
Neutropenia
18
Precursor Cell Lymphoblastic Leukemia-Lymphoma
17
Multiple Myeloma
15
Lymphoma
14
Hematologic Neoplasms
14
Anemia, Sickle Cell
14
Ovarian Neoplasms
12
Myeloproliferative Disorders
10
Leukemia, Lymphocytic, Chronic, B-Cell
10
Fanconi Anemia, Complementation Group D1
10
Venous Thrombosis
9
Primary Myelofibrosis
9
Lung Neoplasms
9
Leukemia, Myelomonocytic, Chronic
9
Prostatic Neoplasms
8
Lymphoma, Non-Hodgkin
8
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Hodgkin Disease
8
Pulmonary Embolism
7
Hemophilia A
7
Interventions
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Hemorrhagic Disorders
×
Classical hematology
×
Clear all
NCT02055781
2021-11-18
PAC326
CTI BioPharma
Phase 3
Terminated
311 enrolled
12 charts